Abstract 184P
Background
Pancreatic cancer remains a highly lethal malignancy with limited treatment options for metastatic and recurrent cases. Nanoliposomal-irinotecan and fluorouracil with leucovorin (NFF) has emerged as the standard treatment following gemcitabine-based regimens. However, the relationship between treatment outcomes and neutropenia in pancreatic cancer has not been thoroughly investigated.
Methods
In this retrospective study, we analyzed data from 161 patients with pancreatic cancer treated with NFF. Neutropenia was assessed based on the Common Terminology Criteria for Adverse Events (CTCAE) cutoffs: Cutoff A (CTCAE Grade 0 versus Grade 1–4), Cutoff B (Grade 0–1 versus Grade 2–4), and Cutoff C (Grade 0–2 versus Grade 3–4). The primary endpoint was overall survival (OS), while secondary endpoints included response rate (RR), progression-free survival (PFS), and relative dose intensity (RDI).
Results
Among the 161 patients, 93/8/22/30/8 had Grade 0/1/2/3/4 neutropenia, respectively. Baseline patient characteristics, including white blood cell (WBC) count, neutrophil count, lymphocyte count, C-reactive protein (CRP) levels, and FU RDI, exhibited significant differences (p<0.05) between two groups separated by Cutoff A and Cutoff B. Additionally, WBC count, neutrophil count, and FU RDI differed significantly (p<0.05) at Cutoff C. Fisher’s exact test revealed significant differences (p<0.05) in RR at Cutoff C, with the odds ratio of Cutoff C being the greatest, followed by Cutoff B and A. Regarding OS, there were significant differences at Cutoff A (hazard ratio (HR), 0.65; 95% CI, 0.44–0.94; p<0.05) and Cutoff B (HR, 0.63; 95% CI, 0.43–0.92; p<0.05), but not at Cutoff C (HR, 0.73; 95% CI, 0.47–1.14; p=0.16). Furthermore, there were significant differences in PFS at Cutoff A and B (p<0.05). Cox regression analysis indicated that neutropenia was significantly associated with OS at Cutoff A and B (adjusted p<0.05).
Conclusions
NFF-induced neutropenia exhibits significant potential as both a predictive factor for treatment response and a prognostic factor for OS in patients with pancreatic cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
221P - Genetic polymorphism of genes encoding cytokines interleukin1 1-alpha and TNF-alpha in non-muscle invasive bladder cancer
Presenter: Anil Kumar
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract
227P - Proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions
Presenter: Changlim Hyun
Session: Poster Display
Resources:
Abstract